LAG3 and melanoma: The phase II/III RELATIVITY-047 trial demonstrated that the combination of nivolumab and relatlimab, an anti-LAG-3 monoclonal antibody, significantly prolonged progression-free survival (PFS) compared to nivolumab monotherapy in patients with advanced melanoma (median PFS: 10.1 months vs. 4.6 months, respectively) [105].